Fig. (3).
Examples of tumor-homing peptides and peptide-drug conjugates. (a) AEZS-108, in which the chemotherapeutic doxorubicin is conjugated to a modified LHRH peptide for the treatment of castration-resistant prostate cancer. (b) Conjugation of the anti-apoptotic α-TOS to the HER2-targeting peptide, LTVSPWY. (c) Octreotide and (d) lanreotide, two somatostatin analogues developed as both anti-tumor agents and targeting moieties).